Compare Stocks

→ How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$10.46 -0.1%	$14.86	$8.13 ▼ $43.69	$375.41M	-0.53	974,305 shs	8,978 shs
JYNT Joint	$12.16 +0.7%	$11.71	$7.31 ▼ $16.48	$181.67M	1.59	88,619 shs	490 shs
OPT Opthea	$3.44 -5.2%	$3.56	$1.60 ▼ $4.42	$200.90M	1.19	23,113 shs	1,754 shs
XAIR Beyond Air	$1.21 +2.9%	$1.63	$1.13 ▼ $6.36	$43.58M	-0.18	306,292 shs	12,300 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-2.79%	-6.18%	-29.97%	-36.51%	-66.26%
JYNT Joint	-1.63%	+1.34%	-3.13%	+27.70%	-24.26%
OPT Opthea	+6.12%	+7.06%	-1.89%	+35.32%	-5.20%
XAIR Beyond Air	-8.20%	-1.26%	-30.47%	-17.83%	-78.85%

It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	1.0502 of 5 stars	3.4	0.0	0.0	0.0	3.3	0.6
JYNT Joint	1.3845 of 5 stars	3.2	1.0	0.0	0.0	1.7	1.9
OPT Opthea	1.4542 of 5 stars	3.5	3.0	0.0	0.6	0.8	0.6
XAIR Beyond Air	3.6305 of 5 stars	3.5	2.0	3.5	1.1	0.8	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	2.75	Moderate Buy	$53.13	407.89% Upside
JYNT Joint	2.33	Hold	$21.50	76.81% Upside
OPT Opthea	3.00	Buy	$14.00	306.98% Upside
XAIR Beyond Air	3.00	Buy	$11.25	830.29% Upside

Current Analyst Ratings

Latest JYNT, OPT, XAIR, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
4/2/2024	BMEA Biomea Fusion	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$51.00 ➝ $14.00
4/1/2024	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
4/1/2024	BMEA Biomea Fusion	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
3/6/2024	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
2/6/2024	BMEA Biomea Fusion	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
JYNT Joint	$117.70M	1.54	$0.72 per share	16.92	$1.68 per share	7.24
OPT Opthea	$110K	1,826.33	N/A	N/A	($0.10) per share	-34.40
XAIR Beyond Air	N/A	N/A	N/A	N/A	$1.40 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$117.25M	-$3.46	N/A	N/A	N/A	N/A	-69.35%	-59.65%	5/7/2024 (Estimated)
JYNT Joint	-$9.75M	-$0.66	N/A	24.32	N/A	-8.19%	7.80%	2.65%	5/2/2024 (Confirmed)
OPT Opthea	-$142.52M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
XAIR Beyond Air	-$55.82M	-$2.13	N/A	N/A	N/A	N/A	-199.90%	-106.00%	6/27/2024 (Estimated)

Latest JYNT, OPT, XAIR, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2024	N/A	JYNT Joint	-$0.03	N/A	+$0.03	N/A	N/A	N/A
4/1/2024	Q4 2023	BMEA Biomea Fusion	N/A	-$0.98	-$0.98	-$0.98	N/A	N/A
3/7/2024	Q4 2023	JYNT Joint	$0.03	$0.07	+$0.04	$0.89	$29.63 million	$30.61 million
2/12/2024	12/31/2023	XAIR Beyond Air	-$0.61	-$0.50	+$0.11	-$0.50	$0.49 million	$0.39 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
JYNT Joint	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
XAIR Beyond Air	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	7.84	7.84
JYNT Joint	0.08	1.32	1.32
OPT Opthea	N/A	N/A	N/A
XAIR Beyond Air	0.61	3.39	3.26

Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
JYNT Joint	76.88%
OPT Opthea	55.95%
XAIR Beyond Air	31.50%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	26.27%
JYNT Joint	4.00%
OPT Opthea	3.20%
XAIR Beyond Air	19.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	103	35.89 million	26.46 million	Optionable
JYNT Joint	444	14.94 million	14.34 million	Optionable
OPT Opthea	24	58.40 million	56.53 million	Not Optionable
XAIR Beyond Air	98	36.04 million	29.19 million	Optionable

JYNT, OPT, XAIR, and BMEA Headlines

Source	Headline
	Beyond Paradise's dating storyline is a breath of fresh air digitalspy.com - April 12 at 6:47 PM
	Beyond the Horizon Air and Space Show ends with record number of spectators msn.com - April 10 at 1:56 PM
	Beyond the Horizon Air Show attracts thousands to Maxwell AFB wsfa.com - April 7 at 2:22 PM
	Beyond Air (NASDAQ:XAIR) Trading 3.2% Higher marketbeat.com - April 5 at 12:43 AM
	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? zacks.com - March 21 at 1:01 PM
	Beyond Air Prices Direct Offering Of $16 Mln Of Shares, Warrants markets.businessinsider.com - March 20 at 6:51 PM
	Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants globenewswire.com - March 20 at 9:00 AM
	"There is a great need to look for mobility alternatives and we are going to operate with electric vehicles in the air" lapoliticaonline.com - March 18 at 11:59 PM
	Beyond Paradise star teases a different side to her character in season 2 yahoo.com - March 16 at 11:37 PM
	Will Renewed Nvidia Excitement Lift the Entire Market? realmoney.thestreet.com - February 23 at 10:34 AM
	Bed Bath & Beyond has a new CEO, air quality’s rising impact on real estate and more yahoo.com - February 20 at 5:50 PM
	Beyond Air (XAIR) Earnings Dates & Reports investing.com - February 13 at 10:29 PM
	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript msn.com - February 13 at 12:27 PM
	Recap: Beyond Air Q3 Earnings benzinga.com - February 12 at 9:23 PM
	Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates msn.com - February 12 at 9:23 PM
	Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 finance.yahoo.com - February 12 at 4:22 PM
	Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 finance.yahoo.com - February 12 at 4:22 PM
	A Preview Of Beyond Air's Earnings benzinga.com - February 9 at 2:21 PM
	AI model gives air quality forecasts that are similar to weather forecasts msn.com - February 3 at 10:01 PM
	Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast finance.yahoo.com - January 18 at 1:43 PM
	Beyond Air Inc (XAIR) may enjoy gains as insiders got busy in the recent days knoxdaily.com - January 2 at 12:58 PM
	Medical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Study msn.com - December 27 at 12:25 PM
$Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors$	Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors finance.yahoo.com - December 27 at 12:25 PM
	Beyond Air Independent Director Acquires 102% More Stock finance.yahoo.com - December 23 at 9:57 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Best Bear Market Funds: Top 3 Investment Options to Consider
March 27, 2024 10:58 AM
View Best Bear Market Funds: Top 3 Investment Options to Consider
Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
Here are the Pros and Cons of Using Options Call Debit Spreads
April 11, 2024 11:03 PM
View Here are the Pros and Cons of Using Options Call Debit Spreads
ASML Fires Warning Shot For Tech Investors
April 17, 2024 9:05 AM
View ASML Fires Warning Shot For Tech Investors
Robinhood’s Credit Card Has Call Option Buyers Coming in Hot
April 3, 2024 8:45 AM
View Robinhood’s Credit Card Has Call Option Buyers Coming in Hot

All Headlines

Company Descriptions

Biomea Fusion

NASDAQ:BMEA

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Joint

NASDAQ:JYNT

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Opthea

NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Beyond Air

NASDAQ:XAIR

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial